We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.84%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$15.7B
AUM Growth
+$958M
(+6.5%)
Cap. Flow
-$459M
Cap. Flow
% of AUM
-2.93%
Top 10 Holdings %
Top 10 Hldgs %
22.96%
Holding
925
New
41
Increased
262
Reduced
364
Closed
130
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$97.5M |
| 2 |
PayPal
PYPL
|
+$66.8M |
| 3 |
HOLX
Hologic
HOLX
|
+$44.4M |
| 4 |
BioNTech
BNTX
|
+$35M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$34.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$80.5M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$79.5M |
| 3 |
Apple
AAPL
|
+$55.8M |
| 4 |
ONC
BeOne Medicines Ltd
ONC
|
+$44.9M |
| 5 |
Verizon
VZ
|
+$37.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.29% |
| 2 | Technology | 26.69% |
| 3 | Financials | 8.86% |
| 4 | Communication Services | 7.82% |
| 5 | Consumer Discretionary | 7.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Relay Therapeutics
RLAY
$4.06B
| $16.3M | 0.1% |
529,885
-33,053
| -6% | -$1.04M |
|
202
Southern Copper
SCCO
$141B
| $16.1M | 0.1% |
281,544
-26,860
| -9% | -$1.5M |
|
203
Cogent Biosciences
COGT
$6.91B
| $16M | 0.1% |
1,865,772
-61,477
| -3% | -$534K |
|
204
UDR
UDR
$12.8B
| $16M | 0.1% |
+266,730
| New | +$15M |
|
205
Becton Dickinson
BDX
$43.8B
| $16M | 0.1% |
65,149
-569
| -0.9% | -$136K |
|
206
CEVA Inc
CEVA
$980M
| $15.8M | 0.1% |
366,080
+6,411
| +2% | +$286K |
|
207
Newmont
NEM
$98.5B
| $15.6M | 0.1% |
251,313
-4,487
| -2% | -$254K |
|
|
ATH
208
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $15.5M | 0.1% |
186,230
-32,830
| -15% | -$2.69M |
|
209
Celldex Therapeutics
CLDX
$2.8B
| $15M | 0.1% |
387,221
+206,999
| +115% | +$9.02M |
|
210
Guardant Health
GH
$19.3B
| $14.7M | 0.09% |
147,289
+22,917
| +18% | +$2.37M |
|
211
Zebra Technologies
ZBRA
$12.6B
| $14.7M | 0.09% |
24,715
+2,187
| +10% | +$1.24M |
|
212
Travelers Companies
TRV
$81.4B
| $14.7M | 0.09% |
93,853
+69,997
| +293% | +$10.9M |
|
213
Bank of Montreal
BMO
$125B
| $14.7M | 0.09% |
136,170
-51,556
| -27% | -$5.56M |
|
214
Fate Therapeutics
FATE
$283M
| $14.7M | 0.09% |
250,737
| – | – |
|
215
Ecolab
ECL
$76.4B
| $14.7M | 0.09% |
62,506
+1,545
| +3% | +$349K |
|
216
DexCom
DXCM
$28.3B
| $14.6M | 0.09% |
108,976
+87,744
| +413% | +$12.6M |
|
217
DuPont de Nemours
DD
$18.9B
| $14.4M | 0.09% |
142,196
-21,620
| -13% | -$2.06M |
|
218
Keros Therapeutics
KROS
$202M
| $14.1M | 0.09% |
240,946
| – | – |
|
219
Replimune Group
REPL
$724M
| $14.1M | 0.09% |
519,512
-2,629
| -0.5% | -$78.6K |
|
220
Pacira BioSciences
PCRX
$1.04B
| $13.8M | 0.09% |
230,081
+25,121
| +12% | +$1.39M |
|
221
Etsy
ETSY
$7.96B
| $13.6M | 0.09% |
62,097
+11,983
| +24% | +$2.89M |
|
|
222
Verizon
VZ
$198B
| $13.4M | 0.09% |
257,602
-727,174
| -74% | -$37.9M |
|
|
GWB
223
DELISTED
Great Western Bancorp, Inc.
GWB
| $13.3M | 0.09% |
392,323
+118,683
| +43% | +$4.05M |
|
224
Wells Fargo
WFC
$264B
| $13.1M | 0.08% |
273,166
-32,893
| -11% | -$1.62M |
|
225
Cigna
CI
$77B
| $13.1M | 0.08% |
56,841
+20,721
| +57% | +$4.4M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2021 Portfolio in Review
As of Q4 2021, Candriam SCA held 925 positions worth $15.7B, up 6.5% from $14.7B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Candriam SCA's Q4 2021 filing shows 41 new, 262 increased, 364 reduced and 130 closed positions. Its largest new stake was Couchbase: 858,038 shares worth $21.4M. The largest sale was Merck, an estimated $80.5M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
- Candriam SCA's largest Q4 2021 buy was Couchbase: 858,038 shares worth $21.4M.
- Candriam SCA added most to Eli Lilly in Q4 2021, an estimated $97.5M increase.
- Candriam SCA's biggest Q4 2021 reduction was Merck, cutting an estimated $80.5M.
- Candriam SCA fully exited Acceleron Pharma in Q4 2021, selling an estimated $79.5M.
- Candriam SCA's ten largest holdings make up 23% of its $15.7B portfolio in Q4 2021.
- Candriam SCA opened 41 new positions and closed 130 in Q4 2021.
- Candriam SCA's portfolio value rose 6.5% quarter-over-quarter to $15.7B.
Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.